6 min read
1 min read
Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial
Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.
A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer.
In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including:- Slow recruitment
- Data cleansing post-MSU
- Multi-site location, process, and staffing

Meet Veristat. Learn More.
- Partner of Choice for Biologics
- Oncology & Hematology Expertise
- Full-Service Clinical Development Solutions
Get the Latest News
Categories
- Regulatory Consulting (118)
- Regulatory Submissions (113)
- Clinical Trial Regulations (96)
- COVID-19 (46)
- Strategic Consulting (28)
- Clinical Trials (24)
- Life At Veristat (21)
- Events (16)
- Success Stories (13)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Oncology (9)
- Clinical Operations/Monitoring (8)
- Medical Writing (8)
- Full-Service (7)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Rare Diseases (1)
2 min read
ASCO Annual Meeting
Apr 23, 2025 Veristat Events
Meet Veristat at the 2025 ASCO Annual Meeting
Advancing Oncology Therapies for Patients in Need
Veristat is proud to...